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Abstract
Focal adhesion kinase (FAK) inhibitors have been developed as potential anticancer agents and are under-
going clinical trials. In vitro activation of the FAK kinase domain triggers autophosphorylation of Y397, Src
activation, and subsequent phosphorylation of other FAK tyrosine residues. However, how FAK Y397 muta-
tions affect FAK kinase-dead (KD) phenotypes in tumour angiogenesis in vivo is unknown. We developed three
Pdgfb-iCreert-driven endothelial cell (EC)-specific, tamoxifen-inducible homozygous mutant mouse lines: FAK
wild-type (WT), FAK KD, and FAK double mutant (DM), i.e. KD with a putatively phosphomimetic Y397E
mutation. These ECCre+;FAKWT/WT, ECCre+;FAKKD/KD and ECCre+;FAKDM/DM mice were injected subcutaneously
with syngeneic B16F0 melanoma cells. Tumour growth and tumour blood vessel functions were unchanged
between ECCre+;FAKWT/WT and ECCre−;FAKWT/WT control mice. In contrast, tumour growth and vessel density
were decreased in ECCre+;FAKKD/KD and ECCre+;FAKDM/DM mice, as compared with Cre− littermates. Despite
no change in the percentage of perfused vessels or pericyte coverage in either genotype, tumour hypoxia was
elevated in ECCre+;FAKKD/KD and ECCre+;FAKDM/DM mice. Furthermore, although ECCre+;FAKKD/KD mice showed
reduced blood vessel leakage, ECCre+;FAKDM/DM and ECCre−;FAKDM/DM mice showed no difference in leakage.
Mechanistically, fibronectin-stimulated Y397 autophosphorylation was reduced in Cre+;FAKKD/KD ECs as compared
with Cre+;FAKWT/WT cells, with no change in phosphorylation of the known Src targets FAK-Y577, FAK-Y861,
FAK-Y925, paxillin-Y118, p130Cas-Y410 . Cre+;FAKDM/DM ECs showed decreased Src target phosphorylation lev-
els, suggesting that the Y397E substitution actually disrupted Src activation. Reduced VE-cadherin-pY658 levels
in Cre+;FAKKD/KD ECs were rescued in Cre+FAKDM/DM ECs, corresponding with the rescue in vessel leakage in the
ECCre+;FAKDM/DM mice. We show that EC-specific FAK kinase activity is required for tumour growth, angiogen-
esis, and vascular permeability. The ECCre+;FAKDM/DM mice restored the KD-dependent tumour vascular leakage
observed in ECCre+;FAKKD/KD mice in vivo. This study opens new fields in in vivo FAK signalling.
© 2017 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd on behalf of Pathological Society of Great Britain
and Ireland.
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Introduction
Tumour growth and spread require angiogenesis. Under-
standing the molecular mechanisms by which tumour
blood vessels develop in vivo is necessary for a better
understanding of the drivers of tumour angiogenesis.
Focal adhesion kinase (FAK) is a 125-kDa non-receptor
tyrosine kinase involved in tumour angiogenesis [1,2].
Upon activation by various stimuli, including inte-
grins and growth factors, FAK autophosphorylation
at Y397 leads to binding and activation of Src, which
in turn phosphorylates other FAK residues, including
Y576, Y577, Y861, and Y925 [3,4]. Apart from its
role as a kinase, FAK also plays a role as a scaffolding
protein, with binding sites for several proteins, making
FAK a central player in cellular processes that include
© 2017 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd on behalf of Pathological Society of Great Britain and Ireland.
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adhesion, migration, invasion, cell proliferation, and
apoptosis [4,5].
We have previously shown that Pdgfb-iCreert-
inducible endothelial cell (EC)-specific homozy-
gous deletion of FAK leads to reduced primary tumour
growth and angiogenesis [2]. Other reports have indi-
cated that hemizygous EC-specific FAK kinase-dead
(KD) mice show no effect on primary tumour growth,
but show reduced vascular endothelial growth fac-
tor (VEGF)-stimulated vascular permeability [6] and
metastasis [7]. These data have supported the devel-
opment of pharmacological FAK kinase inhibitors.
Indeed, inhibition of FAK kinase activity reduced vas-
cular permeability and metastasis [6,7]. Similar results
were obtained with Src inhibitors and in Src-null mice
[8]. FAK and Src may act in concert to regulate vascular
permeability and metastasis [7]. Mice that are haplo-
insufficient for FAK expression show increased tumour
growth and angiogenesis, indicating a dose-dependent
role for FAK [9], and this has raised the notion that
homozygous FAK KD animals may show a different
tumour angiogenic phenotype in vivo.
To further delineate which domains of FAK regu-
late these phenotypes in vivo, we have recently gen-
erated a series of endothelial-specific inducible mutant
FAK knockin mice [10]. In this study, we used the
FAK-K454R mutant, which is KD [11], and a double
mutant (DM) that carries both the KD mutation and a
glutamate substitution of Y397 (Y397E), in order to test
the requirement for FAK autophosphorylation and Src
recruitment. Unlike previously published FAK-mutant
mice, in our system, upon tamoxifen induction, Cre
recombinase is activated in ECs, leading to deletion
of endogenous FAK and expression of a myc-tagged
knockin FAK under control of the Rosa26 (R26) pro-
moter, in both alleles. Thus, after recombination in ECs,
the endogenous FAK is replaced by the myc-tagged
FAK, expressed under control of the R26 promoter, at a
dose similar to that of endogenous FAK. As the knockin
FAK is expressed under control of the R26 promoter,
our system does not reflect any changes due to FAK pro-
moter regulation [10], as other models have [6,7,12].
Materials and methods
Full information on the methods and reagents used in
this study are available in supplementary materials and
methods.
Mice
The work described was approved by the QMUL
Ethics Committee. To study the effect of inducible
EC-specific FAK mutations in vivo, we used a knock-
out/knockin system whereby endogenous mouse FAK
was deleted and myc-tagged chicken FAK [wild-type
(WT) or mutant] was expressed under control of the
R26 promoter upon tamoxifen induction. We developed
Pdgfb-iCreert;FAKfl/fl;R26FAKKD/KD mice (FAK KD)
and Pdgfb-iCreert;FAKfl/fl;R26FAKDM/DM DM mice,
in which Y397 has been additionally mutated to a
glutamate. Pdgfb-iCreert;FAKfl/fl;R26FAKWT/WT mice
expressed WT FAK, and were used to validate the
system. The generation and characterization of these
mice, together with proof of chicken FAK knockin,
have been described previously [10].
Tumour growth assays
Mice aged 12–16weeks were given tamoxifen (Sigma,
Irvine, UK) via intraperitoneal injection on two consecu-
tive days; 3 days later, 106 B16F0mousemelanoma cells
(ATCC) were injected subcutaneously into the flanks
of these mice. Mice were given a tamoxifen-containing
diet (Tamoxifen400; Harlan Laboratories, Blackthorn,
Bicester, UK), from the day of the second tamoxifen
injection until the end of the experiment. Tumour sizes
were measured with digital calipers on alternate days.
Mice were killed by day 18 after tumour cell injec-
tion. Tumour volumes were calculated with the for-
mula volume= length×width2 × 0.52. Tumours were
snap-frozen in isopentane chilled in liquid nitrogen.
Four tumour growth experiments per genotype were per-
formed.
Tumour immunohistochemistry
Counting and image analysis were performed with
an epifluorescence Zeiss Axioplan Microscope (Zeiss,
Munich, Germany). High-quality images were captured
with a Carl Zeiss LSM 710 confocal microscope.
Blood vessel density
Frozen sections were fixed with cold acetone for
10min, blocked with 1% bovine serum albumin (BSA)
in phosphate-buffered saline (PBS), incubated with a
rat anti-endomucin antibody (clone V.7c7, 1:200; Santa
Cruz Biotechnology, Dallas, TX, USA) overnight at
4 ∘C, washed in PBS, and then incubated for 60min at
room temperature with an Alexa Fluor-labelled anti-rat
antibody (A-21208, 1:200; Invitrogen, Loughborough,
UK). Tumour blood vessels were counted across entire
midline sections, and the numbers were expressed as
vessels per mm2 of tumour section.
Functional vessel analysis
Mice with size-matched tumours were tail vein-injected
with 100 μl of 200 μg/ml phycoerythrin (PE)-conjugated
anti-PECAM antibody (clone 390, neat; Biolegend,
San Diego, CA, USA) 10min before they were
killed. To measure the percentage of functional ves-
sels, tumour sections were stained for endomucin
to identify all tumour blood vessels, and the per-
centage of endomucin-positive vessels that were
PE-PECAM-perfused was calculated.
© 2017 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd J Pathol 2017
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Pericyte coverage
Frozen tumour sections were fixed with cold ace-
tone, blocked in 1% BSA in PBS, washed, incubated
overnight at 4 ∘C with a rabbit anti-NG2 antibody
(AB5320, 1:300; Millipore, Watford, Hertfordshire,
UK) and a rat anti-endomucin antibody (V.7C7, 1:200;
Santa Cruz Biotechnology), washed, incubated with
an Alexa Fluor-488 anti-rabbit antibody and an Alexa
Fluor-546 anti-rat antibody (A21206 and A11081,
both 1:200; Invitrogen) for 1 h at room temperature, and
mounted. The percentage of endomucin-positive vessels
with NG2-positive cells associated was calculated.
Vascular permeability
Mice with size-matched tumours were tail vein-injected
with 100 μl of 4mg/ml Hoechst 33342 1min before
being killed, and with PE-conjugated anti-PECAM anti-
body as described above. Frozen tumour sections were
fixed in cold acetone and mounted. Pictures of 5–10
fields were taken with a× 20 objective lens and anal-
ysed with Image J. Hoechst-positive areas divided by
PE-PECAM-positive areas were calculated to give per-
meability ratios.
Hypoxia analysis
Pimonidazole-HCl (Hypoxyprobe, Burlington, MA,
USA) at 60mg/kg body weight was intraperitoneally
injected 1 h before mice were killed. Frozen tumour
sections were acetone-fixed, incubated overnight at
4 ∘C with a fluorescein isothiocyanate-conjugated
mouse anti-pimonidazole antibody (4.3.11.3, 1:10;
Hypoxyprobe), and then washed and mounted. Sections
were analysed at× 10 objective magnification, with
8–10 pictures per case. The percentage of hypoxic area
over the total section area was calculated.
EC preparation
Mouse lung ECs were isolated from three adult mice
per genotype, as previously described [13]. The purity
of ECs prepared with our method has been estab-
lished [2]. Anti-ICAM2 clone IC2/4 (3C4), (Abd
Serotec, Martinsried, Germany); anti-VECAD clone
11D4.1; (BD Biosciences San Joe, CA, USA) were
used to assess EC purity by flow cytometry on a
Becton Dickinson, Oxford, UK, FACSCalibur instru-
ment. As a negative control, IgG-matched isotypes
were used (data not shown). Cells were immor-
talized by two rounds of infection with polyoma
virus middle T [14]. To ensure maximal Cre-induced
recombination, lung ECs isolated from Cre-positive
mice were transfected with a Cre-encoding plasmid
(pCAG-Cre-IRES2-GFP; Addgene, Cambridge, MA,
USA 26646), and cells isolated from Cre-negative
mice were transfected with the corresponding plasmid
backbone (pCAG-GFP; Addgene 11150). Alternatively,
immortalized cells were maintained in medium con-
taining 500 nM 4-hydroxytamoxifen from day 4 after
isolation.
FAK immunoprecipitation and myc-tag western
blotting
RIPA lysates from immortalized lung ECs or mouse
hearts were used. A Dynabeads protein G immunopre-
cipitation kit (Invitrogen) was used according to the
manufacturer’s instructions. FAK was immunoprecipi-
tated with anti-FAK antibody (clone C20, 1:20; Santa
Cruz Biotechnology) that recognizes all FAK in the cell
(i.e. both mouse and chicken FAK). The bound protein
was eluted and loaded onto Tris-acetate polyacrylamide
gels. Separated proteins were transferred to nitrocellu-
lose, blocked, and probed with anti-myc tag antibody
(clone 9E10, 1:1000; Abcam, Cambridge, UK) or
anti-FAK antibody (mouse anti-FAK, 1:1000; 610088;
BD Transduction Laboratories, Oxford, UK) as a
control.
Results
We generated mouse lines to express a knockin WT
chicken FAK (Pdgfb-iCreert;FAKfl/fl;R26FAKWT/WT), a
KDK454Rmutant chicken FAK (Pdgfb-iCreert;FAKfl/fl;
R26FAKKD/KD), and a DMY397E/K454R chicken FAK
(Pdgfb-iCreert;FAKfl/fl;R26FAKDM/DM) (Figure 1A).
Tamoxifen treatment induced deletion in ECs of the
endogenous mouse FAK, with simultaneous expression
of myc-tagged knockin chicken FAK. These mice are
referred to as ECCre+;FAKWT/WT, ECCre+;FAKKD/KD,
and ECCre+;FAKDM/DM, respectively (Figure 1B–D).
Tamoxifen-treated Pdgfb-iCreert-negative littermates
were used as negative controls. WT chicken FAK has
been shown to fully substitute for mouse FAK in other
systems [15,16], and sequence homology within the
nuclear localization motif and nuclear export signal
sequences of mouse and chicken FAK suggests that the
nuclear localizations of mouse and chicken FAK do not
differ [17,18].
ECs were isolated from Cre-negative FAKfl/fl;
R26FAKWT/WT and Pdgfb-iCreert;FAKfl/fl;
R26FAKWT/WT mice, and treated with tamoxifen in
vitro to generate Cre−;FAKWT/WT and Cre+;FAKWT/WT
cells. As antibodies that distinguish between mouse and
chicken FAK do not currently exist, we used the myc-tag
to identify knockin FAK expression. Immunoprecipi-
tation of EC lysates with an antibody that recognizes
both mouse and chicken FAK, followed by western
blotting for myc-tag, showed that the myc-tagged
knockin FAK was expressed in Cre+;FAKWT/WT but
not in Cre−;FAKWT/WT ECs. To assess the expression
of knockin FAK in vivo, fresh hearts were isolated
from tamoxifen-treated ECCre−;FAKWT/WT and
ECCre+;FAKWT/WT mice and lysed. Immunopre-
cipitation of FAK followed by western blotting for
myc-tag showed that the myc-tagged chicken FAK
protein was expressed in whole heart tissue from
ECCre+;FAKWT/WT but not from Cre−;FAKWT/WT
mice (Figure 2A). Quantitative polymerase chain
© 2017 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd J Pathol 2017
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Figure 1. Generation of Pdgfb-iCreert;FAKfl/fl;R26FAKWT/WT, Pdgfb-iCreert;FAKfl/fl;R26FAKKD/KD and Pdgfb-iCreert;FAKfl/fl;R26FAKDM/DM mice. (A)
Schematic representation of WT FAK, the K454R KD mutant FAK and the DM harbouring both the K454R and Y397E mutations. (B–D)
Schematic representations of Pdgfb-iCreert;FAKfl/fl;R26FAKWT/WT, Pdgfb-iCreert;FAKfl/fl;R26FAKKD/KD and Pdgfb-iCreert;FAKfl/fl;R26FAKDM/DM
mouse genotypes. Endogenous FAK is floxed, and knockin chicken FAK mutants were produced as homozygotes. Administration of tamoxifen
induces endogenous mouse FAK deletion and WT, KD or DM knockin chicken FAK expression, to generate (B) ECCre+ FAKWT/WT, (C)
ECCre+ FAKKD/KD, and (D) ECCre+ FAKDM/DM mice, respectively.
reaction (qPCR) analysis demonstrated loss of endoge-
nous mouse FAK mRNA in Cre+;FAKWT/WT but not
Cre−;FAKWT/WT ECs and hearts (Figure 2B). Together,
these data indicate that the knockin WT chicken FAK
was expressed and that the endogenous mouse FAK
was deleted in ECs from ECCre+;FAKWT/WT mice and
in vivo.
Loss of EC FAK in adult mice reduces tumour growth
and tumour angiogenesis [2]. To show that WT chicken
FAK could reproduce the effects of endogenous mouse
© 2017 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd J Pathol 2017
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Figure 2. ECCre+;FAKWT/WT mice and ECCre−;FAKWT/WT mice show similar tumour growth and angiogenesis. (A) Immunoprecipitation (IP)
for FAK and Western blotting (WB) for the myc-tag demonstrate increased myc expression in Cre+;FAKWT/WT EC lysates as compared
with Cre−;FAKWT/WT control lysates, indicating WT chicken FAK knockin expression in the Cre+ ECs. Knockin was also verified in vivo,
by similar analysis of fresh heart lysates made from tamoxifen-treated PdgfbCre+;FAKfl/fl;R26FAKWT/WT (ECCre+ FAKWT/WT) mice, but
not PgdfbCre−;FAKfl/fl;R26FAKWT/WT (ECCre−;FAKWT/WT) mice. WB for FAK indicated that the knockin was expressed at a similar level to
endogenous FAK. The images shown are representative of five experiments. (B) qPCR analysis of mouse FAK shows reduced endogenous
mouse FAK mRNA in Cre+;FAKWT/WT EC lysates and ECCre+;FAKWT/WT fresh heart lysates, as compared with Cre− controls. The graphs
represent mean values± standard errors of the mean (SEMs) relative to the glyceraldehyde-3-phosphate dehydrogenase gene; n= 5
replicates. (C) Tumour growth was not statistically different between ECCre−;FAKWT/WT and ECCre+;FAKWT/WT mice injected subcutaneously
with 1million B16F0 cells. The graph represents means± SEMs; n= 13 (ECCre−;FAKWT/WT) and n= 15 (ECCre+;FAKWT/WT). (D–H) Sections
of end-stage tumours grown in ECCre−;FAKWT/WT and ECCre+;FAKWT/WT mice were analysed by immunohistochemistry for: (D) blood vessel
density (arrows, endomucin-positive blood vessels); (E) blood vessel perfusion (arrows, PE-PECAM/endomucin-positive blood vessels);
(F) pericyte coverage of blood vessels (arrowheads, NG2/endomucin-positive blood vessels); (G) tumour hypoxia (dotted lines delineate
pimonidazole-positive tumour areas); and (H) blood vessel leakage (dotted lines delineate Hoechst-positive areas around PE-PECAM-positive
blood vessels). No significant differences in any of these features was observed between tumours grown in ECCre−;FAKWT/WT and
ECCre+;FAKWT/WT mice. Representative immunofluorescence images are shown. Scale bars: 100 μm in (D), (E), (F) and (H); 250 μm in (G).
Quantification is given as scatter plots: points represent mean values for each mouse, with means± SEMs for each genotype. n= 4–6 mice
per genotype. BV, blood vessels; DAPI, 4′,6-diamidino-2-phenylindole; nsd, no statistically significant difference.
© 2017 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd J Pathol 2017
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FAK in vivo, we first examined tumour growth and
angiogenesis in Pdgfb-iCreert;FAKfl/fl;R26FAKWT/WT
mice. ECCre−;FAKWT/WT and ECCre+;FAKWT/WT
mice were injected subcutaneously with 1million
syngeneic mouse B16F0 melanoma cells, and tumour
growth was measured over time. There was no differ-
ence in tumour growth between ECCre−;FAKWT/WT
and ECCre+;FAKWT/WT mice (Figure 2C). The salient
features of tumour blood vessels were then anal-
ysed histologically, including blood vessel density,
blood vessel perfusion, pericyte coverage, tumour
hypoxia, and blood vessel leakage. Blood vessel
density (number of endomucin-positive vessels per
mm2 of age-matched, size-matched tumour sections)
was unchanged between B16F0 tumours grown in
ECCre−;FAKWT/WT and ECCre+;FAKWT/WT mice
(Figure 2D). To measure blood vessel perfusion, mice
were injected ante mortem via the tail vein with a
PE-labelled anti-PECAM antibody (PE-PECAM) to
label perfused vessels. Tumour sections were then
immunostained for endomucin to identify all vessels.
The percentage of endomucin-positive vessels also
positive for PE-PECAM was not significantly different
between ECCre−;FAKWT/WT and ECCre+;FAKWT/WT
mice (Figure 2E). To examine pericyte coverage of
tumour blood vessels, which is indicative of their
maturation, sections were double-immunostained
for the pericyte marker NG2 and the endothelial
marker endomucin. The percentage of NG2-positive
blood vessels was similar between tumours grown
in ECCre−;FAKWT/WT and ECCre+;FAKWT/WT mice
(Figure 2F). Changes in tumour hypoxia constitute an
indicator of aberrant tumour blood vessel development.
Tumour hypoxia, assessed in vivo by ante mortem
injection of pimonidazole and measurement of areas of
pimonidazole-positive tumour sections, did not differ
between ECCre−;FAKWT/WT and ECCre+;FAKWT/WT
mice (Figure 2G). To examine blood vessel leakage,
mice were injected ante mortem with Hoechst dye
and PE-PECAM. Leakage was analysed by mea-
suring the Hoechst area relative to the endothelial
PE-PECAM-positive area, and showed no difference
between ECCre−;FAKWT/WT and ECCre+;FAKWT/WT
mice (Figure 2H). Together, these data indicate that
EC-specific WT myc-tagged chicken FAK knockin has
no significant effect on tumour growth or tumour blood
vessels, and confirms that the chicken FAK knockin can
rescue the deleted mouse FAK in this system.
We next sought to compare the in vivo effect of
EC-specific FAK KD mutation, alone or in combi-
nation with the phosphomimetic Y397E mutation (in
DM mice). To confirm the endogenous FAK dele-
tion and the knockin (KD or DM) FAK expression,
Cre−;FAKKD/KD, Cre+;FAKKD/KD, Cre−;FAKDM/DM
and Cre+;FAKDM/DM mouse lung ECs were isolated
and lysed. Immunoprecipitation of FAK followed by
western blotting for myc-tag showed that the FAK KD
or the FAK DM myc-tagged proteins were expressed
in Cre+;FAKKD/KD and Cre+;FAKDM/DM ECs but not
in Cre-negative controls (Figure 3A). qPCR analysis
confirmed loss of endogenous mouse FAK mRNA in
Cre+;FAKKD/KD and Cre+;FAKDM/DM ECs, but not
in Cre-negative controls (Figure 3B). Immunofluores-
cence analysis demonstrated that FAK and myc-tag
colocalized in cultured ECs in Cre+;FAKWT/WT,
Cre+;FAKKD/KD and Cre+;FAKDM/DM cells (supple-
mentary material, Figure S1).
ECCre−;FAKKD/KD, ECCre+;FAKKD/KD, ECCre−;
FAKDM/DM and ECCre+;FAKDM/DM mice were injected
subcutaneously with B16F0 melanoma cells. Tumour
growthwas reduced in ECCre+;FAKKD/KD mice as com-
pared with ECCre−;FAKKD/KD controls (Figure 3C).
Tumour growth alsowas reduced in ECCre+;FAKDM/DM
mice as compared with ECCre−;FAKDM/DM mice
(Figure 3D). Immunohistochemical analysis of
end-stage midline tumour sections indicated lower
endomucin-positive blood vessel densities in ECCre+;
FAKKD/KD and ECCre+;FAKDM/DM mice than in
ECCre−;FAKKD/KD and ECCre−;FAKDM/DM mice,
respectively (Figure 3E–G).
As in the ECCre−;FAKWT/WT and ECCre+;
FAKWT/WT mice described above, we next analysed
blood vessels in sections of tumours grown in ECCre−;
FAKKD/KD and ECCre+;FAKKD/KD mice. No differ-
ences in blood vessel perfusion (Figure 4A) or NG2
pericyte association (Figure 4B) were observed between
blood vessels of tumours grown in ECCre−;FAKKD/KD
and ECCre+;FAKKD/KD mice. Tumour hypoxia,
measured by relative pimonidazole levels, showed
a non-significant (p< 0.06) increase in tumours grown
in ECCre+;FAKKD/KD mice (Figure 4C), correlating
with the reduced blood vessel density in these mice.
Hoechst blood vessel leakage was decreased in tumours
grown in ECCre+;FAKKD/KD mice as compared with
ECCre−;FAKKD/KD controls (Figure 4D), suggesting
that the KD mutation was sufficient to affect leakage.
The effect of a FAK Y397E mutation in combi-
nation with the KD mutation was then studied, in
ECCre+;FAKDM/DM mice. Immunohistochemical anal-
ysis of tumour sections from ECCre−;FAKDM/DM and
ECCre+;FAKDM/DM mice again showed no significant
differences in blood vessel perfusion or NG2-positive
pericyte association (Figure 5A, B), similarly to the
results shown in Figure 4A, B. Analysis of tumour
hypoxia showed that pimonidazole levels were higher
in tumours grown in ECCre+;FAKDM/DM mice than in
tumours grown in ECCre−;FAKDM/DM controls, corre-
lating with the reduced blood vessel density observed in
the tumours in ECCre+;FAKDM/DM mice (Figure 5C).
In contrast to the results from the ECCre+;FAKKD/KD
mice, blood vessel leakage of Hoechst dye was no
different in ECCre+;FAKDM/DM mice from that in
ECCre−;FAKDM/DM controls (Figure 5D), suggesting
that the effect of the FAK KD mutation was overcome
by the additional FAK Y397E mutation.
To begin to explain the changes in tumour growth
and tumour blood vessels seen in ECCre+;FAKKD/KD
and ECCre+;FAKDM/DM mice, we analysed ECs from
these mice. Cre+;FAKWT/WT, Cre+;FAKKD/KD and
Cre+;FAKDM/DM ECs were trypsinized and allowed
© 2017 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd J Pathol 2017
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Figure 3. ECCre+;FAKKD/KD mice show reduced tumour growth and associated angiogenesis, and this is not rescued in ECCre+;FAKDM/DM
mice. (A) Immunoprecipitation (IP) for FAK and Western blotting (WB) for the myc-tag demonstrates increased myc-tag expression in
Cre+;FAKKD/KD EC lysates as compared with Cre−;FAKKD/KD control lysates, and in Cre+;FAKDM/DM EC lysates as compared with Cre−;FAKDM/DM
control lysates, indicating mutant FAK knockin expression in Cre+ ECs. FAK WB shows similar expression levels of endogenous and knockin
FAK. Blots are representative of three experimental repeats. (B) qPCR analysis of mouse FAK shows reduced endogenous mouse FAK mRNA
levels in Cre+;FAKKD/KD EC lysates as compared with Cre−;FAKKD/KD control lysates, and in Cre+;FAKDM/DM EC lysates as compared with
Cre−;FAKDM/DM control lysates. Graphs represent mean values± standard errors of the mean, relative to the glyceraldehyde-3-phosphate
dehydrogenase gene; n= 2 experimental repeats. (C, D) B16F0 tumour cells were injected subcutaneously into (C) ECCre−;FAKKD/KD
(n= 14) and ECCre+;FAKKD/KD (n= 15) mice, or (D) ECCre−;FAKDM/DM (n= 13) and ECCre+;FAKDM/DM (n= 16), mice and tumour growth
was monitored over time. (E, F) Endomucin-positive blood vessel density was quantified in midline tumour sections from tumours grown
in (E) ECCre−;FAKKD/KD and ECCre+;FAKKD/KD mice, or (F) ECCre−;FAKDM/DM and ECCre+;FAKDM/DM mice. n= 6 tumours per genotype. (G)
Immunofluorescence detection of endomucin-positive blood vessels in tumours grown in ECCre−;FAKKD/KD and ECCre+;FAKKD/KD mice, or
ECCre−;FAKDM/DM and ECCre+;FAKDM/DM mice. Arrows: endomucin-positive blood vessels. Scale bar: 50 μm. Student’s t-test: *p< 0.05,
***p< 0.001. DAPI, 4′,6-diamidino-2-phenylindole.
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Figure 4. Reduced tumour vasculature leakage and enhanced tumour hypoxia in ECCre+;FAKKD/KD mice. Sections of end-stage tumours
grown in ECCre−;FAKKD/KD and ECCre+;FAKKD/KD mice were analysed by immunohistochemistry for: (A) blood vessel perfusion (arrows,
PE-PECAM/endomucin-positive blood vessels); (B) pericyte coverage of blood vessels (arrowheads, NG2/endomucin-positive blood vessels);
(C) tumour hypoxia (dotted lines delineate pimonidazole-positive tumour areas); and (D) blood vessel leakage (dotted lines delineate
Hoechst-positive areas around PE-PECAM-positive blood vessels). Representative immunofluorescence images are shown. Quantification
is given in scatter plots: points represent mean values for individual mice, with means± standard errors of the mean for each genotype.
Scale bars: 100 μm in (A), (B), and (D); 250 μm in (C). Student’s t-test: *p< 0.05. n= 4–6 mice per genotype. BV, blood vessels; DAPI,
4′,6-diamidino-2-phenylindole; nsd, no statistically significant difference.
to attach to fibronectin for 5, 10 or 30min, lysed, and
subjected to Western blotting. As expected, attachment
to fibronectin of Cre+;FAKWT/WT ECs induced phos-
phorylation of FAK on Y397, Y577, Y861, and Y925,
and subsequent phosphorylation of the FAK/Src sub-
strates paxillin and p130Cas. Surprisingly, we detected
no fibronectin adhesion-dependent increase in phos-
phorylation of Src in this context. However, increased
phosphorylation levels of direct Src substrates, such
as FAK-Y577, FAK-Y861, and FAK-Y925, as well as
p130Cas, clearly demonstrated that its kinase activity
was stimulated. Cre+;FAKKD/KD ECs showed reduced
phosphorylation of the FAK kinase target FAK-Y397
as expected, whereas sites of Src-dependent phos-
phorylation were unaffected, including FAK-Y577,
FAK-Y861, FAK-Y925, and p130Cas-Y410. Introduc-
tion of the Y397E mutation into the DM FAK resulted
in a super-inhibited form, and all the substrates tested
© 2017 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd J Pathol 2017
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Figure 5. Tumour vascular leakage is not affected in ECCre+;FAKDM/DM mice. Sections of end-stage tumours grown in ECCre−;FAKDM/DM and
ECCre+;FAKDM/DM mice were analysed by immunohistochemistry for: (A) blood vessel perfusion (arrows, PE-PECAM/endomucin-positive
blood vessels); (B) pericyte coverage of blood vessels (arrowheads, NG2/endomucin-positive blood vessels); (C) tumour hypoxia (dotted
lines delineate pimonidazole-positive tumour areas); and (D) blood vessel leakage (dotted lines delineate Hoechst-positive areas around
PE-PECAM-positive blood vessels). Representative immunofluorescence images are shown. Quantification is given in scatter plots: points
represent mean values for individual mice, with means± standard errors of the mean for each genotype. Scale bars: 100 μm in (A), (B), and
(D); 250 μm in (C). Student’s t-test: **p< 0.01. n= 3–6 mice per genotype. BV, blood vessels; DAPI, 4′,6-diamidino-2-phenylindole; nsd, no
statistically significant difference.
showed greatly reduced phosphorylation, indicating that
both FAK and Src activities were absent in these cells
(Figure 6A). Phosphorylation of targets further down
the signalling pathways, such as Akt and JNK1/2, was
largely unaffected by either FAKmutant (supplementary
material, Figure S2). Together, these data show a rather
global effect on signalling, which does not explain why
ECCre+;FAKDM/DM mice showed restored vascular
leakage as compared with ECCre+;FAKKD/KD mice.
Probably the most studied regulator of vascular per-
meability is VECAD. Previous work has shown that KD
FAK inhibits VECADY658 phosphorylation in vivo and
that this is correlated with reduced vascular leakage [7].
Western blot analysis of Cre+;FAKKD/KD ECs revealed
reduced VECAD-pY658 levels as compared with
Cre+;FAKWT/WT and Cre+;FAKDM/DM ECs, suggesting
that the VECAD-pY658 regulation correlates with
the reduced leakage in ECCre+;FAKKD/KD mice and
rescued the leakage phenotype in ECCre+;FAKDM/DM
mice (Figure 6B). To examine whether the signalling
players involved in permeability also correlated with the
reduced leakage in ECCre+;FAKKD/KD mice, we took
a non-candidate approach in which Cre+;FAKWT/WT,
Cre+;FAKKD/KD and Cre+;FAKDM/DM ECs were
© 2017 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd J Pathol 2017
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Figure 6. The EC FAK Y397E KD double mutation results in dual FAK and Src kinase inhibition and restores VECAD-pY658 levels and
permeability-related signalling as compared with Cre+;FAKKD/KD ECs. (A) Cre+;FAKWT/WT, Cre+;FAKKD/KD and Cre+;FAKDM/DM ECs were allowed
to adhere to fibronectin (FN) for 0, 5, 10 and 30min, lysed, and analysed by western blotting for levels of myc-tag, FAK, pY397-FAK,
pY577-FAK, pY861-FAK, pY925-FAK, pY118-paxillin, paxillin, pY410-p130Cas, p130Cas, pY416-Src, and Src. Glyceraldehyde-3-phosphate
dehydrogenase was used as a loading control. Blots are representative of three experimental repeats. (B) Western blot analysis of
Cre+;FAKWT/WT, Cre+;FAKKD/KD and Cre+;FAKDM/DM EC lysates for VECAD-pY658, total VECAD, and GAPDH as a loading control. The bar
chart represents mean densitometric readings for duplicate samples. (C) Cre+;FAKWT/WT, Cre+;FAKKD/KD and Cre+;FAKDM/DM EC lysates were
subjected to RPPA analysis, and expression levels of β-actin, total IRS-1, IRS-1-pS636/639, XIAP, Tyk2-pY1054/1055 and PLCγ1 are shown.
Bars represent mean values from two experimental repeats.
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subjected to reverse-phase protein array (RPPA) analysis
for 135 different analytes [19]. The expression or activ-
ity of several molecules was altered in Cre+;FAKKD/KD
ECs but not in Cre+;FAKWT/WT or Cre+;FAKDM/DM
ECs. These included β-actin, phospho-S636/639-IRS-1
(but not total IRS-1 levels), XIAP, Tyk2 pY1054/1055,
and PLC-γ1, all of which are known to be mediators of
Src signalling and regulators of permeability [20–27]
(Figure 6C). No changes in phosphorylation of VEGF
receptor 2, another regulator of vascular permeability,
were observed between any of the genotypes (sup-
plementary material, Figure S3), suggesting that this
receptor was not involved in the changes in vascu-
lar permeability observed in the Cre+;FAKKD/KD or
Cre+;FAKDM/DM mice. Together, these data suggest
that the molecular pathways that regulate permeability
are altered in Cre+;FAKKD/KD ECs and restored in
Cre+;FAKDM/DM ECs.
Discussion
We showed previously that endothelial FAK is involved
in tumour growth and angiogenesis [2]. However,
genetic ablation of FAK did not allow us to determine
whether this was due to FAK kinase or scaffolding
activities. Our present data indicate that loss of FAK
kinase activity in ECs leads to a similar phenotype
as the total loss of FAK in ECs, regarding tumour
formation, tumour angiogenesis, and tumour hypoxia
[2]. This reveals the predominant role of FAK intrinsic
kinase activity over its scaffolding functions in tumour
growth. Interestingly, the Y397E substitution, designed
as a phosphomimetic, was not able to rescue the tumour
phenotype observed. However, the structures of phos-
photyrosine and glutamate are very different, and it has
been proposed before that there is no suitable phospho-
tyrosine phosphomimetic mutation [28]. The presence
of glutamate at position Y397 of FAKmay therefore not
allow the binding and activation of Src and other FAK
binding partners, which may explain why this mutant
was unable to correct the KD phenotype. To explore this
further, we investigated the phosphorylation of FAK
and Src-dependent substrates in response to fibronectin
attachment, a well-known FAK/Src stimulus [29]. How-
ever, we observed an increase in Src phosphorylation
in our immortalized FAK KD ECs as compared with
FAK WT cells. This has previously been observed in
immortalized MEF KD cells but not in primary cells
[12]. We also observed high basal levels of phospho-Src
in WT cells, also possibly due to the immortalization,
making phospho-Src an unreliable target to follow.
We therefore explored the phosphorylation status of
FAK-Y397, which depends on FAK kinase activity, and
known Src targets [30–34]. Consistent with previous
results, we observed no inhibition of Src activity in the
FAK KD ECs [6] and only a reduction in pY397-FAK
levels, confirming previous results showing that Src is
able to phosphorylate this site independently of FAK
kinase activity [35]. In the FAK DM ECs however,
we observed a profound reduction in phosphorylation
of all targets. In vitro, the DM ECs behaved very
similarly to ECs expressing a mutated form of FAK
in which exon 15, which codes for 19 amino acids,
including Y397, was deleted (FAKΔ15) [36]. Whereas
the trans-autophosphorylation activity and therefore
the kinase activity of FAKΔ15 were unaffected, phos-
phorylation of FAK-Y576/77 and FAK-Y925, as well
as p130Cas and paxillin, in response to fibronectin
plating was absent in this mutant, similarly to what we
observed with the FAK DM ECs. This strongly supports
the hypothesis that, in this DM, the glutamate sub-
stitution actually profoundly disrupted Src activation.
This is in agreement with previous studies showing the
importance of Y397 as a binding site for Src, rather
than in FAK kinase activation, and the need for both
kinases to act as a complex for efficient phosphorylation
of substrates [32].
Interestingly, there was a reduction in vascular leak-
age in the ECCre+;FAKKD/KD mouse tumour vessels
that was, however, corrected in the vessels of the
ECCre+;FAKDM/DM mice. Both FAK and Src kinases
activities have been previously shown to regulate
VEGF-induced permeability in vivo, with a reduction in
vascular permeability in response to genetic deletion of
FAK or Src, or in response to pharmacological inhibitors
of these targets [6,37]. Surprisingly, in our study, inhi-
bition of both kinases together reversed this decreased
permeability. This suggests that, whereas inhibition of
either kinase alone is sufficient to modulate EC barrier
strengthening, Src and FAK probably act as a complex in
this process, and either need each other’s kinase activity
or, as has been suggested in previous reports, regulate
each other’s intracellular localization and thereby down-
stream signalling [7,32,38]. Additionally, we show that
VECAD phosphorylation at Y658 is downregulated in
Cre+;FAKKD/KD ECs and rescued in Cre+;FAKDM/DM
ECs. This correlates with reduced leakage in the
Cre+;FAKKD/KD mice, and is accompanied by alter-
ations in the levels of β-actin, IRS-1-pS636/639, XIAP,
Tyk2 pY1054/1055 and PLCγ1 in Cre+;FAKKD/KD
ECs, but not in Cre+;FAKDM/DM ECs, as compared
with Cre+;FAKWT/WT ECs. Indeed, these molecules are
known to play a role in Src signalling and vessel per-
meability [20–27], and the changes observed correlate
with reduced leakage in ECCre+;FAKKD/KD mice that
is rescued in ECCre+;FAKDM/DM mice. Together, these
results suggest that FAK kinase activity and Src work
in concert to control VECAD activity and upstream
molecular pathways.
Our data regarding tumour formation differ from the
data in a 2014 study [7], in which it was shown that
FAKKD expression in the endothelium leads to reduced
metastasis without affecting primary tumour growth.
One should, however, keep in mind the differences
between the mouse models used in these studies, as
others have used a system in which FAK mutants are
expressed in a hemizygous state, whereas, in our cur-
rent study, FAK mutants are expressed by both alleles.
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The role of FAK as a dose-dependent regulator of angio-
genesis has previously been stressed. FAK heterozy-
gous mice do not phenocopy WT FAK mice, and, in
fact, show enhanced tumour angiogenesis and tumour
growth [9]. Thus, as the mice in the above study [7]
are hemizygous for WT or KD FAK (and not homozy-
gous, as ours are), this may explain the difference in the
results.
We have used EC-specific FAK knockin mutants
homozygously expressed to help determine the roles
of the kinase domain and Y397 residue in vivo in
tumour growth and angiogenesis. Overall, our data show
that inhibiting FAK kinase activity in ECs is suffi-
cient to reduce tumour growth and angiogenesis, and
strongly support the use of FAK inhibitors in the clinic
[39]. The reduction in vascular leakage observed in
ECCre+;FAKKD/KD mice suggests that these inhibitors
might have additional positive effects in vivo, as they
would be expected to reduce vascular permeability, and
therefore improve normalization and drug delivery, and
also potentially reduce metastasis [7,40]. Outside the
context of oncology, it would be interesting to test the
effects of FAK kinase inhibitors in ischaemic tissues,
where VEGF-induced permeability has deleterious con-
sequences, exacerbating tissue injury and infarct size
[40]. The use of other knockin mutants should help to
further delineate FAK signalling in physiological and
pathological processes in vivo.
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Supplementary materials and methods
Supplementary figure legends
Figure S1. Immunofluorescence analysis demonstrates myc-tag and FAK co-localisation in cultured Cre+;FAKWT/WT, Cre+;FAKKD/KD and
Cre+;FAKDM/DM ECs
Figure S2.No apparent changes in Akt, JNK1/2 or ERK1/2 levels or phosphorylation in Cre+;FAKWT/WT, Cre+;FAKKD/KD and Cre+;FAKDM/DM ECs
Figure S3. No apparent changes in VEGF-receptor 2 in Cre+;FAKWT/WT, Cre+;FAKKD/KD and Cre+;FAKDM/DM ECs
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